Substituted dioxopiperidinyl phthalimide derivatives
    5.
    发明授权
    Substituted dioxopiperidinyl phthalimide derivatives 有权
    取代的二氧代哌啶基邻苯二甲酰亚胺衍生物

    公开(公告)号:US09045453B2

    公开(公告)日:2015-06-02

    申请号:US13107873

    申请日:2011-05-13

    申请人: Roger Tung

    发明人: Roger Tung

    IPC分类号: C07D401/00 C07D401/04

    摘要: This invention relates to novel substituted dioxopiperidinyl phthalimide derivatives and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an immunomodulatory agent.

    摘要翻译: 本发明涉及新的取代的二氧代哌啶基邻苯二甲酰亚胺衍生物及其药学上可接受的酸加成盐。 本发明还提供包含本发明化合物的组合物以及这些组合物在治疗由免疫调节剂有益治疗的疾病和病症的方法中的用途。

    Morphinan compounds
    6.
    发明授权
    Morphinan compounds 有权
    吗啡化合物

    公开(公告)号:US08541436B2

    公开(公告)日:2013-09-24

    申请号:US13118935

    申请日:2011-05-31

    申请人: Roger Tung

    发明人: Roger Tung

    IPC分类号: A61K31/4748 C07D221/22

    摘要: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.

    摘要翻译: 本公开涉及新的吗啡喃化合物及其衍生物,其药学上可接受的盐,溶剂合物和水合物。 本公开还提供了包含本公开的化合物的组合物以及该组合物在治疗通过施用也具有NMDA拮抗剂活性的σ1受体激动剂有益治疗的疾病和病症的方法中的用途。

    Deuterated benzo[D][1,3]-dioxol derivatives
    7.
    发明授权
    Deuterated benzo[D][1,3]-dioxol derivatives 有权
    氘代苯并[D] [1,3] - 二氧杂环戊烯衍生物

    公开(公告)号:US08450492B2

    公开(公告)日:2013-05-28

    申请号:US12688466

    申请日:2010-01-15

    申请人: Roger Tung

    发明人: Roger Tung

    IPC分类号: C07D211/22

    摘要: The present invention relates to an isotopologue of Compound 1 substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to Compound 1. They may also be used to accurately determine the concentration of Compound 1 in biological fluids and to determine metabolic patterns of Compound 1 and its isotopologues. The invention further provides compositions comprising these deuterated isotopologues and methods of treating diseases and conditions that are responsive to increased neuronal serotonin transmission, alone and in combination with additional agents.

    摘要翻译: 本发明涉及在苯并二氧杂环戊烯的亚甲基碳上被氘取代的化合物1的同位素学。 本发明的同位素学选择性5-羟色胺再摄取抑制剂(SSRIs)并且与化合物1相比具有独特的生物药物和代谢性质。它们还可用于精确测定化合物1在生物流体中的浓度并确定化合物1及其化合物1的代谢模式 同位素学。 本发明还提供包含这些氘代同位素异构体的组合物和治疗对增加的神经元血清素传递起反应的疾病和病症的方法,其单独和与另外的试剂组合。

    Heterocyclic kinase inhibitors
    8.
    发明授权
    Heterocyclic kinase inhibitors 有权
    杂环激酶抑制剂

    公开(公告)号:US08338425B2

    公开(公告)日:2012-12-25

    申请号:US12331431

    申请日:2008-12-09

    申请人: Roger Tung

    发明人: Roger Tung

    IPC分类号: A61K31/497 C07D403/14

    摘要: This invention relates to novel 2-{6-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-2-methyl-pyrimidin-4-ylamino}-thiazole-5-carboxylic acid (2-chloro-6-methyl-phenyl)-amide derivatives, and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by the inhibition of kinases including Src-kinase and Bcr-Abl kinase.

    摘要翻译: 本发明涉及新的2- {6- [4-(2-羟基 - 乙基) - 哌嗪-1-基] -2-甲基 - 嘧啶-4-基氨基} - 噻唑-5-羧酸(2-氯 - 6-甲基 - 苯基) - 酰胺衍生物及其药学上可接受的酸加成盐。 本发明还提供包含本发明化合物的组合物和这些组合物在治疗通过抑制包括Src-激酶和Bcr-Abl激酶的激酶有益治疗的疾病和病症的方法中的用途。

    PYRAZINOISOQUINOLINE COMPOUNDS
    9.
    发明申请
    PYRAZINOISOQUINOLINE COMPOUNDS 有权
    吡咯烷酮化合物

    公开(公告)号:US20120149709A1

    公开(公告)日:2012-06-14

    申请号:US13256787

    申请日:2010-03-16

    摘要: This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.

    摘要翻译: 本发明涉及吡嗪并异喹啉衍生物的新化合物及其药学上可接受的盐。 更具体地,本发明涉及作为吡喹酮衍生物的新型吡嗪异喹啉衍生物。 本发明还提供包含一种或多种本发明化合物和载体的组合物,以及所述化合物和组合物在治疗通过施用抗栓剂如吡喹酮有益治疗的疾病和病症的方法中的用途。

    4-AMINOQUINAZOLINE PRODRUGS
    10.
    发明申请

    公开(公告)号:US20110300132A1

    公开(公告)日:2011-12-08

    申请号:US12986135

    申请日:2011-01-06

    CPC分类号: C07F9/65586

    摘要: This invention relates to prodrugs of 4-aminoquinazoline compounds, and to pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of the EGFR and HER2.

    摘要翻译: 本发明涉及4-氨基喹唑啉化合物的前药及其药学上可接受的盐。 本发明还提供了包含本发明化合物的组合物和这些组合物在治疗通过施用EGFR和HER2的抑制剂有益治疗的疾病和病症的方法中的用途。